Roll-Out to Commercialization
Dr. Flatt says that SGI, through its supported research at JCVI, has developed a “one-pot, isothermal method to assemble pieces of DNA rapidly and accurately.” SGI is applying the platform to develop cyanobacteria for production of products ranging from biofuels to food and feed ingredients. Scientists at JCVI and SGI are also developing what they describe as a pioneering methodology to transplant whole genomes into recipient cells.
SGI says its milestones to date follow its predicted trajectory of the commercialization of synthetic biology products.
“The first products will likely be synthetic genomic tool-based products that facilitate more rapid, cost-effective synthesis and assembly of DNA molecules for both research and commercial purposes. Soon thereafter, we expect to see seasonal flu vaccines, developed from commercialized vaccine seeds,” says Dr. Flatt.
“Subsequently, one can expect to see engineered microbial biocatalysts and processes designed around commercialized biocatalysts—first in food and feed markets and, later, in agriculture and biofuels. The specific time frames to commercialize products in each of these fields is partially dependent upon receiving regulatory approvals both for products and manufacturing processes, which are unique to each market.”